Tag: Intravenous
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 – 09/12/2022 at 08:00
Additional positive TG6002 Phase I data show that the oncolytic virus is able to reach the tumor, replicate and express its payload in all patients when administered intravenously Strasbourg, France,…